- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00998946
Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Beverly Hills, California, United States, 90211
- Tower Cancer Research Foundation
-
-
Idaho
-
Post Falls, Idaho, United States, 83854
- Kootenai Cancer Center
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
-
Kentucky
-
Louisville, Kentucky, United States, 40245
- Owsley Brown Frazier Cancer Center
-
-
Louisiana
-
Shreveport, Louisiana, United States, 71101
- Overton Brooks VA Medical Center
-
-
Montana
-
Billings, Montana, United States, 59102
- Frontier Cancer Center and Blood Institute
-
-
New York
-
New York, New York, United States, 10016
- New York University Hospital
-
-
Oregon
-
Portland, Oregon, United States, 97225
- Providence Cancer Center
-
-
Tennessee
-
Memphis, Tennessee, United States, 38120
- The West Clinic (ACORN)
-
-
Wisconsin
-
La Crosse, Wisconsin, United States, 54601
- Gundersen Lutheran
-
Madison, Wisconsin, United States, 53705-2275
- University of Wisconsin, Paul P. Carbone Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically/cytologically confirmed, measurable (lesion or node =2 cm by CT [at least 1 cm if by spiral CT]) B-cell Non-Hodgkin's Lymphoma, using the Revised European American Lymphoma (REAL) World Health Organization (WHO) disease classification
- Progressive or persistent disease after ≥ 1 prior treatment(s)
- Recovered from toxic effects of prior treatment
- At least 4 weeks since most recent cytotoxic therapy
- Easter Cooperative Oncology Group (ECOG) performance status ≤ 2
- Adequate blood, liver, and kidney functions as defined by laboratory levels
- 1.0 mg/day orally of folic acid for at least 7 days prior & 1 mg intramuscular of vitamin B12 within 10 weeks of the planned start of pralatrexate
- Females of childbearing potential must agree to use medically acceptable birth control from start of pralatrexate until at least 30 days after the last administration of pralatrexate and must have a negative serum pregnancy test within 14 days prior to the first day of study treatment
- Males who are not surgically sterile must agree to use medically acceptable birth control from start of pralatrexate until at least 90 days after the last administration of pralatrexate
- Available for repeat dosing and follow-up
- Able to give written informed consent
Exclusion Criteria:
- Relapsed participants with diffuse large B-cell lymphoma (DLBCL) who are candidates for high-dose therapy and autologous stem cell transplantation (SCT) and for whom high-dose therapy and autologous SCT is a standard curative option
- Active concurrent malignancy (except non-melanoma skin cancer or carcinoma in situ of the cervix). If there is a history of prior malignancies other than those exceptions listed above, the participant must be disease-free for ≥ 5 years. Participants with other prior malignancies < 5 years before study entry may still be enrolled if they have received treatment resulting in complete resolution of the cancer and currently have no clinical, radiologic, or laboratory evidence of active or recurrent disease
- Congestive heart failure Class III/IV according to the New York Heart Association Functional Classification
- Uncontrolled hypertension
- Known human immunodeficiency virus (HIV)-positive diagnosis
- Symptomatic central nervous system (CNS) metastases or lesions for which treatment is required. Participants who received prophylactic CNS treatment are eligible.
- Participants who have undergone an allogeneic SCT
- Participants who have relapsed < 100 days from the time of an autologous SCT
- Participants with disease refractory to peripheral blood SCT or who have relapsed < 100 days from the time of transplant
- Active uncontrolled infection, underlying medical condition, or other serious illness that would impair the ability of the participant to receive protocol treatment.
- Major surgery within 14 days of enrollment
- Receipt of any conventional chemotherapy or radiation therapy (encompassing a substantial [> 10%] amount of bone marrow) within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study treatment or planned use during the course of the study
- Receipt of systemic corticosteroids within 1 week of study treatment, unless participant has been taking a continuous dose of no more than 10 mg/day of prednisone or its equivalent for at least 1 month
- Use of any investigational drugs, biologics, or devices within 4 weeks prior to study treatment or planned use during the course of the study
- Previous exposure to pralatrexate
- Females who are pregnant or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pralatrexate
Participants received pralatrexate at an initial dose of 30 mg/m^2, as IV push over 30 seconds to 5 minutes via a patent free-flowing IV line containing normal saline on Days 1, 8 and 15 of a 4-week cycle (weekly for 3 weeks with 1 week of rest) until criteria for discontinuation per protocol were met. The initial dose of 30 mg/m^2 may be reduced to 20 mg/m^2 weekly, permitted per protocol defined criteria. If pralatrexate 20 mg/m^2/week was not tolerated, pralatrexate had to be discontinued. Dose re-escalation was not allowed once dose reduction was done. Participants had dietary supplement of vitamin B12 and folic acid along with pralatrexate. Vitamin B12, given as 1mg IM, within 10 weeks of start of pralatrexate dosing, every 8-10 weeks throughout the study and for at least 30 days post last dose of pralatrexate. Folic acid was given 1mg daily, orally, for at least 7 days prior to start of pralatrexate, throughout the study and for at least 30 days post last dose of pralatrexate. |
Pralatrexate injection administered as intravenous (IV) push
Other Names:
1 mg intramuscular (IM) injection
Other Names:
Oral 1 mg tablet
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: Up to 24 months
|
Objective response rate was defined as the percentage of participants with a complete response (CR) or a partial response (PR).
Tumor response was evaluated on the basis of clinical and radiological criteria, assessed according to International Workshop Criteria (IWC) with or without positron emission tomography (PET) scans.
Per IWC criteria CR is defined as complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy, and normalization of those biochemical abnormalities definitely assignable to non-Hodgkin's lymphoma (NHL) and PR is defined as >= 50% decrease in sum of the product of the perpendicular diameters (SPD) of the six largest dominant nodes or nodal masses and no increase in size of other nodes, liver or spleen.
|
Up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Response (DOR)
Time Frame: Up to 24 months
|
The Duration of Response was defined as the time (in months) from the date the measurement criteria were first met for CR or PR (whichever status was recorded first) until the first subsequent date that relapse or progression was documented.
It was assessed according to IWC with or without PET, subject to its availability.
Per IWC, progression was defined as a ≥50% increase from the nadir in the individual sum of the products of the diameters of any index lesion; the reappearance of pathology, enlargement of liver/spleen, or unequivocal progression of non-measurable disease or appearance of any new lesions.
|
Up to 24 months
|
Progression Free Survival (PFS)
Time Frame: Up to 24 months
|
Progression-free survival (PFS) was the duration of time (in months) from first administration of study treatment to date of first documented progression or death from any cause.
It was based on tumor assessments made according to the IWC with or without PET scans, subject to their availability.
Per IWC, progression was defined as a ≥50% increase from the nadir in the individual sum of the products of the diameters of any index lesion; the reappearance of pathology, enlargement of liver/spleen, or unequivocal progression of non-measurable disease or appearance of any new lesions.
|
Up to 24 months
|
Overall Survival (OS)
Time Frame: Up to 24 months
|
Overall Survival was the time (in months) from first administration of study treatment until the date of death.
|
Up to 24 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Non-Hodgkin
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Micronutrients
- Hematinics
- Folic Acid Antagonists
- Vitamins
- Folic Acid
- Vitamin B 12
- Hydroxocobalamin
- Vitamin B Complex
- 10-deazaaminopterin
Other Study ID Numbers
- PDX-015
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma, B-Cell
-
Iksuda Therapeutics Ltd.RecruitingFollicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Non-Hodgkin LymphomaAustralia, Canada, United States
-
Massachusetts General HospitalVarian Medical SystemsNot yet recruitingLymphoma, B-Cell | Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Lymphoma | High-grade B-cell Lymphoma | Relapsed Cancer | Mediastinal Large B-cell LymphomaUnited States
-
Nathan DenlingerBristol-Myers SquibbRecruitingB-Cell Non-Hodgkin Lymphoma-Recurrent | Diffuse Large B-Cell Lymphoma-Recurrent | Follicular Lymphoma-Recurrent | High Grade B-Cell Lymphoma-Recurrent | Primary Mediastinal Large B-Cell Lymphoma-Recurrent | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent and other conditionsUnited States
-
University Hospital Southampton NHS Foundation...Hoffmann-La RocheTerminatedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited Kingdom
-
University of ChicagoMerck Sharp & Dohme LLCRecruitingLymphoma | Lymphoma, B-Cell | B Cell Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell LymphomaUnited States
-
The Lymphoma Academic Research OrganisationActive, not recruitingRefractory Indolent Adult Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Diffuse Large B-Cell Lymphoma Refractory | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Refractory Primary Mediastinal Large B-Cell Cell LymphomaFrance
-
AstraZenecaRecruitingFollicular Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | B-cell Non Hodgkin LymphomaKorea, Republic of, United States, Japan, Australia, Taiwan
-
Memorial Sloan Kettering Cancer CenterRecruitingLymphoma | Lymphoma, B-Cell | DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma | Large-cell Lymphoma | Mediastinal B-Cell Diffuse Large Cell LymphomaUnited States
-
Curocell Inc.RecruitingHigh-grade B-cell Lymphoma | Diffuse Large B-cell Lymphoma (DLBCL) | Primary Mediastinal Large B-Cell Lymphoma (PMBCL) | Transformed Follicular Lymphoma (TFL) | Refractory Large B-cell Lymphoma | Relapsed Large B-cell LymphomaKorea, Republic of
-
University of WashingtonAstraZenecaRecruitingB-Cell Non-Hodgkin Lymphoma | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Transformed Follicular Lymphoma to Diffuse...United States
Clinical Trials on Pralatrexate
-
Samsung Medical CenterCompletedRelapsed or Refractory Peripheral T-cell LymphomaKorea, Republic of
-
Taiwan Mundipharma Pharmaceuticals Ltd.UnknownPeripheral T Cell Lymphoma | Progression, DiseaseTaiwan
-
Acrotech Biopharma Inc.CompletedPeripheral T-cell LymphomaUnited States, United Kingdom, Canada, France, Italy, Belgium
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)Completed
-
Stanford UniversityNational Comprehensive Cancer NetworkCompletedMultiple MyelomaUnited States
-
Acrotech Biopharma Inc.Axis Clinicals LimitedCompletedPeripheral T-Cell Lymphoma (PTCL)United States
-
Spectrum Pharmaceuticals, IncTerminatedPeripheral T-cell LymphomaBelgium, Spain, United States, Australia, France, Israel, Canada, United Kingdom, New Zealand, Italy, Ireland, Poland, Puerto Rico
-
Jennifer AmengualColumbia UniversityWithdrawnLymphoma, T-Cell, Peripheral
-
Jennifer AmengualCompletedLymphoma | Multiple Myeloma | Hodgkin Lymphoma | Lymphoid Malignancies | Non-hodgkin LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States